In short
Clinical trials investigating Apadamtase Alfa are studying whether it is safe and effective for people with thrombotic thrombocytopenic purpura, including immune-mediated and congenital forms. The trials look at treatment given either as prevention or on demand, and they measure safety, tolerability, and other outcomes.
Key points
- Clinical trials of Apadamtase Alfa are focused on thrombotic thrombocytopenic purpura, including immune-mediated TTP and congenital TTP. One study is Phase 2 and looked at treatment with minimal to no plasma exchange in 36 patients with iTTP. Another is Phase 3 and studied long-term safety in 75 patients with cTTP using prophylactic and on-demand treatment. The main results measured safety, tolerability, and treatment-related adverse events. The Phase 3 study did not use a primary efficacy endpoint because safety was the main goal. Both trials were completed.
Trial overview
Two clinical trials investigated Apadamtase Alfa in people with thrombotic thrombocytopenic purpura, a rare blood disorder. One trial studied immune-mediated TTP, and the other studied congenital TTP.
Both studies were interventional, which means researchers gave a treatment and then checked the results.
Conditions studied
The first trial focused on immune-mediated thrombotic thrombocytopenic purpura (iTTP), a form of TTP linked to the immune system.
The second trial focused on congenital thrombotic thrombocytopenic purpura (cTTP), which is the inherited form of the disease and is present from birth.
These trials did not study other conditions, based on the source data provided.
Study designs and phases
NCT05714969 was a Phase 2 study and looked at treatment with minimal to no plasma exchange in patients with iTTP.
NCT04683003 was a Phase 3 continuation study and evaluated prophylactic and on-demand treatment in people with cTTP.
In the source data, the Phase 3 study states that there was no primary efficacy endpoint because the main objective was long-term safety.
Who participated
The Phase 2 iTTP study enrolled 36 participants.
The Phase 3 cTTP study enrolled 75 participants.
From the trial records provided, the target groups were people with either immune-mediated TTP or congenital TTP.
What was measured
The main outcome in the Phase 2 study was the incidence of adverse events, serious adverse events, and special interest adverse events after any dose of the study treatment.
The Phase 3 study measured long-term safety and tolerability, including treatment-emergent adverse events and serious adverse events in both the prophylactic and on-demand groups.
These outcomes show that the trials were mainly designed to learn how safe the treatment was in these patient groups, rather than to compare many different disease outcomes.
Key points for patients
Apadamtase Alfa was studied in two completed trials, both in rare forms of TTP.
One study tested a Phase 2 approach in iTTP with minimal to no plasma exchange, while the other tested Phase 3 long-term use in cTTP with preventive and on-demand treatment.
The main focus across both studies was safety, including adverse events and serious adverse events.
Because the source data are limited to these two trials, this article only reflects the trial details provided here.